A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis.
OBJECTIVE
Tolerability and safety of 0.1% tacrolimus ointment in treating nickel-induced allergic contact dermatitis (ACD) were evaluated.


METHODS
Patients allergic to nickel applied nickel patches to each upper inner aspect of the arm for 4 to 8 hours daily. Tacrolimus was applied to patch site on one arm and vehicle to patch site on the other, twice daily. Physician's Global Assessment, signs and symptoms of ACD, pruritus scores, and adverse events were evaluated.


RESULTS
After 8 weeks, dermatitis in 45% of patients was clear or almost clear (Physician's Global Assessment) with tacrolimus; and 1% with vehicle (P < .001). Significant results were achieved as early as day 8. Tacrolimus was superior in ACD signs and symptoms improvement and pruritus reduction (P < .001). Adverse events were similar between treatments.


CONCLUSIONS
This model, involving one agent, may not be generalizable for other agents.


CONCLUSIONS
Tacrolimus ointment 0.1% is well tolerated and significantly more effective than vehicle in treating chronically exposed, nickel-induced ACD.
Belsito
Donald
D
University of Missouri, Kansas City, USA.
Wilson
David C
DC
Warshaw
Erin
E
Fowler
Joseph
J
Ehrlich
Alison
A
Anderson
Bryan
B
Strober
Bruce E
BE
Willetts
Jennifer
J
Rutledge
Edward S
ES
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy* / Q000209:etiology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009532:Nickel / Q000009:adverse effects*; D009824:Ointments; D011446:Prospective Studies; D016559:Tacrolimus / Q000008:administration & dosage*
D007166:Immunosuppressive Agents; D009824:Ointments; D009532:Nickel; D016559:Tacrolimus